Please select the option that best describes you:

Does the magnitude of OncoType recurrence score above 26 inform decision between TC and AC/T in ER+ HER2- 1-3 node positive, postmenopausal patients with breast cancer?  

Is the marginal advantage of AC/T in 1-3 node positive outweighed by toxicity such as risk of cardiotoxicity and leukemia, regardless of RS?



Answer from: Medical Oncologist at Community Practice
Comments
Medical Oncologist at British Columbia Cancer Agency
I would agree with Dr. @Peddi. In HR+HER2- N1 dis...
Medical Oncologist at Onc San Antonio
Drs. @Peddi and @Mitri: Would a score of, let&rsqu...
Medical Oncologist at Colorado Permanente Medical Group Hematology & Oncology
Can you comment a bit on the TC 4 vs TC 6 issue? T...
Medical Oncologist at Clinical Instructor
Dr. @Susan M. Freeman, here is a previous discussi...
Sign in or Register to read more